Phase II trial of Dasatinib monotherapy for Philadelphia positive acute lymphoblastic leukemia in the Elderly

Phase II trial of Dasatinib monotherapy for Philadelphia positive acute lymphoblastic leukemia in the Elderly - DASPAL-E

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007736

Enrollment

Registered

2012-04-12

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Philadelphia positive acutelymphoblastic leukemia

Interventions

dasatinib monotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Ph+ALL/CML-LC 2. age >=55 3. ECOG PS 0-3 4. No indication of HSCT 5. No dysfunction of liver and kidney 6. IC

Exclusion criteria

Exclusion criteria: 1. active double cancer 2. uncontrollable complication 3. past history of TKI/chemotherapy 4. physicians' decision

Design outcomes

Primary

Measure	Time frame
Event free survival rate at 1 year	—

Countries

Japan

Contacts

Public ContactNaoto Takahashi

Study group of DASPAL-E office

theme_crc_takahashi@yahoo.co.jp+81-18-884-6115

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026